Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
3.849
+0.049 (1.28%)
Jan 17, 2025, 4:00 PM EST - Market closed
Aprea Therapeutics Employees
Aprea Therapeutics had 7 employees as of December 31, 2023. The number of employees decreased by 2 or -22.22% compared to the previous year.
Employees
7
Change (1Y)
-2
Growth (1Y)
-22.22%
Revenue / Employee
$187,263
Profits / Employee
-$1,929,595
Market Cap
20.92M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7 | -2 | -22.22% |
Dec 31, 2022 | 9 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
APRE News
- 5 weeks ago - Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward - GlobeNewsWire
- 3 months ago - Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - GlobeNewsWire
- 3 months ago - Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit - GlobeNewsWire
- 3 months ago - Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - GlobeNewsWire
- 3 months ago - Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development - GlobeNewsWire
- 4 months ago - UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire